ArticleMolecular medicine reports2019
Silencing of MALAT1 inhibits migration and invasion by sponging miR‑1‑3p in prostate cancer cells.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Nanomedicine Targeting Cancer-Associated Fibroblasts in Prostate Cancer: From Biological Mechanisms to Integrated Theranostic Strategies.International journal of nanomedicine · 2026Review
- Suppressing CDCA8/CDK1 improves oral squamous cell carcinoma by modulating proliferation, apoptosis, cell cycle and migration.Discover oncology · 2025Article
- Female and male hormonal-dependent malignancies: the role of long non-coding RNAs.Medical oncology (Northwood, London, England) · 2025Review
- Natural products and long non-coding RNAs in prostate cancer: insights into etiology and treatment resistance.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Broadening horizons: molecular mechanisms and disease implications of endothelial-to-mesenchymal transition.Cell communication and signaling : CCS · 2025Review
- TMED3 promotes prostate cancer via FOXO1a and FOXO3a phosphorylation.Oncology research · 2025Article
- LncRNA LOC730101 Promotes Darolutamide Resistance in Prostate Cancer by Suppressing miR-1-3p.Cancers · 2024Article
- Cancer fusion transcripts with human non-coding RNAs.Frontiers in oncology · 2024Review
- Structure-activity relationship study of mesyl and busyl phosphoramidate antisense oligonucleotides for unaided and PSMA-mediated uptake into prostate cancer cells.Frontiers in chemistry · 2024Article
- The important role of miR-1-3p in cancers.Journal of translational medicine · 2023Review
- The axis of long non-coding RNA MALAT1/miR-1-3p/CXCR4 is dysregulated in patients with diabetic neuropathy.Heliyon · 2022Article
- Crosstalk between Long Non Coding RNAs, microRNAs and DNA Damage Repair in Prostate Cancer: New Therapeutic Opportunities?Cancers · 2022Review
- MALAT1 Fusions and Basal Cells Contribute to Primary Resistance against Androgen Receptor Inhibition in TRAMP Mice.Cancers · 2022Article
- Exosomes Derived from Tumor Cells Initiate Breast Cancer Cell Metastasis and Chemoresistance through a MALAT1-Dependent Mechanism.Journal of oncology · 2022Article
- Long non-coding RNA in prostate cancer.American journal of clinical and experimental urology · 2022Review
- The Role of Long Non-Coding RNAs in Epithelial-Mesenchymal Transition-Related Signaling Pathways in Prostate Cancer.Frontiers in molecular biosciences · 2022Review
- Regulation of Neuroendocrine-like Differentiation in Prostate Cancer by Non-Coding RNAs.Non-coding RNA · 2021Review
- Molecular Pathogenesis of the Coronin Family:International journal of molecular sciences · 2021Article
- Actin-Binding Proteins as Potential Biomarkers for Chronic Inflammation-Induced Cancer Diagnosis and Therapy.Analytical cellular pathology (Amsterdam) · 2021Review
- MicroRNA‑199a‑5p suppresses cell proliferation, migration and invasion by targeting ITGA3 in colorectal cancer.Molecular medicine reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is a common malignancy with a high mortality rate. Long non‑coding RNA metastasis associated with lung adenocarcinoma transcript 1 (MALAT1) has been reported to serve tumor‑promoting roles. However, the underlying mechanism requires further examination. In the present study, it was demonstrated that MALAT1 was increased while microRNA (miR/miRNA)‑1‑3p was decreased in prostate cancer cell lines. The silencing of MALAT1 inhibited migration, invasion and epithelial‑mesenchymal transition, when epithelial (E)‑cadherin expression level was increased, and neural (N)‑cadherin, vimentin, Slug and Snail expression levels were decreased. Dual‑luciferase reporter assay results demonstrated that miR‑1‑3p bound to MALAT1 and coronin 1C (CORO1C) 3' untranslated region, and MALAT1 competed with CORO1C for the binding sites of miR‑1‑3p. MALAT1 inhibited the expression of miR‑1‑3p and vice versa. MALAT1 knockdown induced the decline of CORO1C, which was subsequently recovered by the miR‑1‑3p inhibitor. In addition, by inhibiting miR‑1‑3p or overexpressing CORO1C, the silencing of MALAT1‑induced phenotypic alterations were restored. In conclusion, MALAT1 serving as a degradable miRNA sponge, may sequester miR‑1‑3p from CORO1C and by silencing MALAT1, migration, invasion and epithelial‑mesenchymal transition may be inhibited in prostate cancer cells. MALAT1 and CORO1C may serve as novel clinical therapeutic targets for prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.